Mizoribine (MZR)

DRUG2 trials

Sponsors

Asahi Kasei Pharma Corporation

Conditions

Lupus NephritisNephrotic Syndrome

Phase 3

A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis

CompletedNCT02256150

Asahi Kasei Pharma CorporationLupus Nephritis

Start: 2014-11-30End: 2019-03-31Updated: 2019-06-07

A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome

CompletedNCT02257697

Asahi Kasei Pharma CorporationNephrotic Syndrome

Start: 2014-11-30End: 2018-11-30Updated: 2019-01-17

Related Papers

Mizoribine or Cyclophosphamide for Lupus Nephritis

JAMA Network Open2025-03-142 citations

Efficacy and Safety of Mizoribine for the Treatment of Refractory Nephrotic Syndrome: Protocol for a Multicenter, Controlled, Open-label, Randomized Controlled Trial

JMIR Research Protocols2023-03-292 citations